• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38780.14
  • 1.3 %
  • 496.2891
  • FTSE
  • 8296.8
  • 0.42 %
  • 34.72
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Ikena Oncology, Inc. (IKNA) Stock Price, News & Analysis

Ikena Oncology, Inc. (IKNA) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.71

-$0.02

(-1.16%)

Day's range
$1.7
Day's range
$1.72
50-day range
$1.66
Day's range
$1.79
  • Country: US
  • ISIN: US45175G1085
52 wk range
$1.22
Day's range
$2.32
  • CEO: Dr. Mark Manfredi Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.03
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (IKNA)
  • Company Ikena Oncology, Inc.
  • Price $1.71
  • Changes Percentage (-1.16%)
  • Change -$0.02
  • Day Low $1.70
  • Day High $1.72
  • Year High $2.32

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/11/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $1.33
  • High Stock Price Target $1.33
  • Low Stock Price Target $1.33
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.57
  • Trailing P/E Ratio -1.11
  • Forward P/E Ratio -1.11
  • P/E Growth -1.11
  • Net Income $-68,166,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Ikena Oncology, Inc. Frequently Asked Questions

  • What were the earnings of IKNA in the last quarter?

    In the last quarter Ikena Oncology, Inc. earnings were on Thursday, November, 7th. The Ikena Oncology, Inc. maker reported -$0.19 EPS for the quarter, beating analysts' consensus estimates of -$0.27 by $0.08.

  • What is the Ikena Oncology, Inc. stock price today?

    Today's price of Ikena Oncology, Inc. is $1.71 — it has decreased by -1.16% in the past 24 hours. Watch Ikena Oncology, Inc. stock price performance more closely on the chart.

  • Does Ikena Oncology, Inc. release reports?

    Yes, you can track Ikena Oncology, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Ikena Oncology, Inc. stock forecast?

    Watch the Ikena Oncology, Inc. chart and read a more detailed Ikena Oncology, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Ikena Oncology, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Ikena Oncology, Inc. stock ticker.

  • How to buy Ikena Oncology, Inc. stocks?

    Like other stocks, IKNA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Ikena Oncology, Inc.'s EBITDA?

    Ikena Oncology, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Ikena Oncology, Inc.’s financial statements.

  • What is the Ikena Oncology, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -7.4417030568, which equates to approximately -744.17%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Ikena Oncology, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Ikena Oncology, Inc.'s financials relevant news, and technical analysis. Ikena Oncology, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Ikena Oncology, Inc. stock currently indicates a “sell” signal. For more insights, review Ikena Oncology, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.